What is POEMS syndrome?
POEMS syndrome is a rare disorder caused by a small population of abnormal plasma cells. Plasma cells are white blood cells in the bone marrow that normally make antibodies. In POEMS syndrome, a single abnormal group (clone) of plasma cells drives damage to nerves and many other organs.
The name is an acronym for five of its main features:
- Polyneuropathy: damage to the nerves of the arms and legs
- Organomegaly: enlarged liver, spleen or lymph nodes
- Endocrinopathy: hormone problems, such as an underactive thyroid or diabetes
- Monoclonal plasma cell disorder: an abnormal protein (M-protein) in the blood
- Skin changes: such as darkening of the skin or extra hair growth
Not every person has all five features, and other important features are not in the name. These include sclerotic bone lesions (dense, hardened areas of bone), Castleman disease, swelling and fluid build-up, and very high levels of a protein called VEGF (vascular endothelial growth factor) (Dispenzieri, 2023).
POEMS syndrome usually starts in middle age, around 50 years, and is slightly more common in men. It is often misdiagnosed at first, usually as chronic inflammatory demyelinating polyneuropathy (CIDP), a different nerve disease.
POEMS syndrome is treatable. Treatments aimed at the plasma cells, such as radiotherapy, medicines used for myeloma and stem cell transplantation, can control the disease for many years. Most people live more than a decade after diagnosis (Dispenzieri et al., 2003).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of condition | Paraneoplastic syndrome caused by a plasma cell clone |
| How common | Rare; about 0.3 per 100,000 people in a Japanese survey |
| Typical age | Median about 50; range from young adults to the elderly |
| Sex | Slightly more common in men |
| Key features | Nerve damage, M-protein (almost always lambda type), sclerotic bone lesions, high VEGF |
| Key test | Plasma or serum VEGF level, with bone imaging and nerve tests |
| Main treatments | Radiotherapy for limited bone lesions; myeloma-type medicines and stem cell transplant for widespread disease |
| Outlook | Median survival more than a decade |
2. Causes and risk factors
The cause of POEMS syndrome is not known. It is not inherited and not infectious.
How the disease causes damage
The abnormal plasma cells, often only a small number, produce or trigger the release of signalling proteins (cytokines). The most important is VEGF, which makes blood vessels leaky and encourages new vessel growth. Other cytokines, such as IL-6, IL-12 and TNF-alpha, are also raised.
These signals are thought to cause many of the features of POEMS syndrome:
| Effect | Result |
|---|---|
| Leaky blood vessels | Swelling of the legs, fluid in the tummy and around the lungs |
| Nerve damage | Progressive weakness and numbness |
| New blood vessel growth | Skin haemangiomas, enlarged organs |
| Effects on bone | Sclerotic (hardened) bone lesions |
| Effects on blood cells | High platelet or red blood cell counts |
The monoclonal protein
Almost everyone with POEMS syndrome has a lambda light chain M-protein, usually of the IgA or IgG type. The amount is usually small, so it can be missed on routine tests unless a sensitive test called immunofixation is done.
POEMS syndrome and Castleman disease
About 1 in 7 to 1 in 4 people with POEMS syndrome also have Castleman disease, a lymph node disorder with typical microscopic changes. In addition, a Castleman disease variant of POEMS exists, in which people have Castleman disease and many POEMS features but no clear M-protein. These people are treated in a similar way, focusing on the underlying disorder.
3. How does it look
On the body
| Feature | What you may see |
|---|---|
| Skin darkening (hyperpigmentation) | Darker, tanned-looking skin without sun exposure |
| Extra hair growth (hypertrichosis) | Thicker, darker hair on the limbs or body |
| Glomeruloid haemangiomas | Small red or purple raised spots, often on the trunk |
| Plethora and acrocyanosis | Flushed face; bluish-purple hands and feet |
| White nails | Pale nails, sometimes with clubbing |
| Swelling | Puffy legs and ankles, or a swollen tummy |
| Muscle wasting | Thinning of the hand and lower leg muscles from nerve damage |
| Skin thickening | Firm, thickened skin in some people |
On scans
| Test | Typical finding |
|---|---|
| CT of the bones | Dense, sclerotic bone lesions, often with a lytic rim; present in most patients |
| PET-CT | Shows active bone lesions, enlarged lymph nodes and organs |
| Abdominal imaging | Enlarged liver, spleen and lymph nodes; fluid in the abdomen |
| Chest imaging | Fluid around the lungs; sometimes raised lung pressure |
The bone lesions are easily missed on plain X-rays and may look like harmless bone islands. A low-dose CT of the whole skeleton is the recommended test.
In the eye
Swelling of the optic nerve at the back of the eye (papilloedema) is common and may be found during an eye examination.
4. Symptoms
Symptoms usually develop slowly over months. The nerve symptoms are often the first and most troublesome.
Nerve symptoms
- Tingling, numbness or burning in the feet, then the hands
- Weakness of the legs, causing trips, falls or difficulty climbing stairs
- Weak grip and difficulty with buttons or writing
- Pain in the feet and legs
- Difficulty walking, which can progress to needing a wheelchair if untreated
Other symptoms
| Area | Possible symptoms |
|---|---|
| Fluid build-up | Swollen legs, swollen tummy, breathlessness |
| Hormones | Tiredness and weight gain (low thyroid), erectile dysfunction or loss of periods, breast enlargement in men, raised blood sugar |
| Skin | Darkening, extra hair, red spots, flushing |
| General | Tiredness, weight loss, sweating |
| Eyes | Blurred vision or headaches from papilloedema |
| Lungs and heart | Breathlessness from fluid or high lung blood pressure |
| Blood | Blood clots, linked to high platelet counts |
When to seek medical advice
See a doctor about numbness or weakness in the feet or hands that keeps getting worse, particularly if you also have swelling, skin changes or hormone problems. If you have been diagnosed with CIDP and are not improving with standard treatment, ask whether POEMS syndrome has been considered.
5. Diagnosis
Diagnostic criteria
Diagnosis requires both mandatory criteria, at least one major criterion and at least one minor criterion (Dispenzieri, 2023).
| Category | Criteria |
|---|---|
| Mandatory | Polyneuropathy (typically demyelinating); monoclonal plasma cell disorder (almost always lambda) |
| Major (at least 1) | Castleman disease; sclerotic bone lesions; raised VEGF |
| Minor (at least 1) | Organomegaly; extravascular fluid overload; endocrinopathy; skin changes; papilloedema; high platelet or red cell count |
Tests
| Test | Purpose |
|---|---|
| Nerve conduction studies | Show the typical pattern of nerve damage |
| Serum and urine immunofixation | Find the small lambda M-protein |
| Serum free light chains | Measure light chain levels |
| Plasma or serum VEGF | Usually very high; also used to track response |
| Low-dose whole-body CT or PET-CT | Find sclerotic bone lesions and enlarged organs |
| Bone marrow biopsy | Looks for abnormal plasma cells |
| Biopsy of a bone lesion or lymph node | Confirms a plasmacytoma or Castleman disease |
| Hormone tests | Thyroid, adrenal, sex hormones, blood sugar |
| Blood count | High platelets or red cells |
| Eye examination, heart and lung tests | Check for papilloedema, fluid and lung pressure |
Why diagnosis is often delayed
On average, POEMS syndrome is diagnosed more than a year after symptoms start. Several reasons contribute:
- The nerve damage looks like CIDP, which is far more common
- The M-protein is small and can be missed on standard protein electrophoresis
- The bone lesions look harmless on X-rays
- The many different features are often seen by different specialists
A raised VEGF level in a person with a demyelinating neuropathy and a lambda M-protein strongly points to POEMS syndrome (Dispenzieri, 2025).
Conditions that can look similar
| Condition | How it differs |
|---|---|
| CIDP | No lambda M-protein, normal VEGF, no sclerotic bone lesions |
| MGUS-related neuropathy | Often IgM; VEGF normal |
| Multiple myeloma | Larger M-protein, lytic (not sclerotic) bone lesions, anaemia and kidney problems |
| AL amyloidosis | Amyloid deposits; organ damage pattern differs |
6. Treatment
Treatment is aimed at the underlying plasma cell clone. Care is best delivered by a team experienced in plasma cell disorders, with neurology and rehabilitation support.
Limited disease
| Situation | Treatment |
|---|---|
| 1-3 sclerotic bone lesions and no widespread marrow involvement | Radiotherapy to the lesions; can control the disease for years |
Widespread disease
| Treatment | Notes |
|---|---|
| High-dose melphalan with autologous stem cell transplant | For fit patients; produces deep, long-lasting responses (D’Souza et al., 2012) |
| Lenalidomide with dexamethasone | Effective and widely used; requires blood clot prevention |
| Bortezomib-based treatment | Used, with care because bortezomib can worsen nerve damage |
| Daratumumab-based treatment | Increasingly used, especially for relapse |
| Thalidomide with dexamethasone | Studied in Japan; nerve side effects limit use |
| Melphalan with dexamethasone | For those unable to have a transplant |
Supportive care
| Area | Support |
|---|---|
| Physiotherapy | Maintains strength and walking |
| Occupational therapy | Aids for daily tasks and hand function |
| Orthotics | Ankle-foot splints for foot drop |
| Hormone replacement | For thyroid, adrenal or sex hormone deficiency |
| Diuretics | To reduce fluid build-up |
| Blood thinners | When there is a high clot risk |
| Nerve pain medicines | Such as gabapentin, pregabalin or duloxetine |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Radiotherapy | Short daily sessions on weekdays over about 3-5 weeks |
| Tablet treatment | Lenalidomide taken at home in 4-week cycles, with blood tests and clot prevention |
| Stem cell collection | Injections to move stem cells into the blood, then a few hours on a collection machine |
| Transplant | About 2-4 weeks in hospital; recovery of energy over several months |
| Rehabilitation | Ongoing physiotherapy and occupational therapy throughout |
Side effects
| Treatment | Possible side effects |
|---|---|
| Radiotherapy | Tiredness, skin soreness, local effects |
| Stem cell transplant | Infections, mouth sores, tiredness; engraftment syndrome, a fever and rash reaction that is more common in POEMS |
| Lenalidomide | Low blood counts, blood clots, rash, diarrhoea |
| Bortezomib | Worsening nerve damage, low platelets |
| Dexamethasone | High blood sugar, mood changes, sleep problems |
7. Outlook (prognosis)
| Measure | Approximate figures |
|---|---|
| Median survival | About 14 years in a large Mayo Clinic series (Dispenzieri et al., 2003) |
| After stem cell transplant | Most people alive and many free of progression years later (D’Souza et al., 2012) |
| Nerve recovery | Slow; improvement can continue for 2-3 years after treatment (Karam et al., 2015) |
Falling VEGF levels are a useful sign that treatment is working, though nerve function takes much longer to improve.
Factors linked with a poorer outlook
- Fluid overload (pleural effusions, ascites)
- Clubbing of the fingers
- Raised lung blood pressure
- Older age at diagnosis
- Poor response to treatment
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic review | Every 3-6 months to check symptoms and examination |
| VEGF and M-protein tests | Track disease activity |
| Nerve tests | Measure recovery |
| PET-CT or CT | Check bone lesions |
| Hormone tests | Adjust replacement treatment |
9. Living with POEMS syndrome
- Keep active with physiotherapy-guided exercise to maintain strength
- Prevent falls by removing trip hazards and using walking aids if needed
- Check your feet daily for injuries you may not feel
- Be patient with nerve recovery; it often takes years
- Take blood thinners as prescribed if you are on lenalidomide
- Connect with myeloma and rare disease charities for support
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is POEMS syndrome cancer? | It is caused by an abnormal plasma cell clone, related to myeloma, but it usually behaves differently and is treatable |
| Is it the same as myeloma? | No. The plasma cell clone is usually small, and the damage comes from cytokines such as VEGF |
| Will my nerves recover? | Often yes, partly or fully, but recovery is slow |
| Is it inherited? | No |
| Why was I diagnosed with CIDP first? | The nerve damage looks similar, and the M-protein is often small and easily missed |
| Can it come back? | Yes. Relapse is possible, so long-term follow-up with VEGF tests is important |
| Will the skin changes go away? | Skin darkening, extra hair and swelling often improve within months of effective treatment |
| Can I work during treatment? | Many people can, with adjustments; time off is usually needed around a stem cell transplant |
| Do I need to avoid anything? | Avoid falls and foot injuries while sensation is reduced, and follow advice on infection prevention during treatment |
11. Questions to ask your care team
- Which of my symptoms are caused by POEMS syndrome?
- Is my disease limited enough for radiotherapy alone?
- Am I a candidate for stem cell transplantation?
- How will my VEGF and M-protein be monitored?
- What support is available for nerve recovery and mobility?
- Do I need hormone replacement?
Resources
- D’Souza, A. et al. (2012) ‘Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience’, Blood, 120(1), pp. 56-62.
- Dispenzieri, A. (2023) ‘POEMS syndrome: update on diagnosis, risk-stratification, and management’, American Journal of Hematology, 98(12), pp. 1934-1950.
- Dispenzieri, A. (2025) ‘POEMS syndrome: diagnosis, treatments, and outcomes’, Hematology. American Society of Hematology Education Program, 2025(1), pp. 393-400.
- Dispenzieri, A. et al. (2003) ‘POEMS syndrome: definitions and long-term outcome’, Blood, 101(7), pp. 2496-2506.
- Karam, C. et al. (2015) ‘Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome’, Neurology, 84(19), pp. 1981-1987.
- National Cancer Institute (2026) Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.